TABLE 1.
Baseline characteristics of the patients, ophthalmology features, and performed therapies
| Diabetic patients | Control subjects | |
|---|---|---|
| Patients (n)/eyes (n) | 104/109 | 26/26 |
| Sex (male) | 63 (61) | 11 (42) |
| Age (years) | 52 ± 2 | 68 ± 2* |
| A1C (%) | 6.9 ± 2.8 | — |
| Type 1/type 2 diabetes | 72/32 | — |
| Insulin treatment | 73 (70) | — |
| Eyes with PDR (n) | 98 with/11 without | — |
| Creatinin clearance (ml/min) | 74.3 ± 3.8 | 74.8 ± 4.6 |
| Hypertension | 77 (74) | 13 (50) |
| Dyslipidemia | 53 (51%) | 5 (18) |
| Smoking | 32 (31) | 6 (22) |
| Ophthalmology features (n eyes) | ||
| PDR | 98 (90) | 0 |
| PDR with vitreous haemorrhage | 63 | 0 |
| PDR with tractional retinal detachment | 22 | 0 |
| PDR or macular edema | 14 | 0 |
| Epimacular membrane | 8 (7) | 16 (62) |
| Macular hole | 0 | 6 (23) |
| Rhegmatogenous retinal detachment | 3 (3) | 2 (8) |
| Age-related macular degenerescence | 0 | 2 (8) |
| Therapies | ||
| Intravitreal injection of Bevacizumab | 12 (11) | — |
| No panretinal laser photocoagulation | 13 (13.2) | — |
| Incomplete panretinal laser photocoagulation | 58 (59.2) | — |
| Complete panretinal laser photocoagulation | 27 (27.5) | — |
Data are n (%) unless otherwise indicated.
*Significant difference between diabetic and control patients.